Recently, Professor Guo Hui from Department of Medical Oncology of the First Affiliated Hospital (FAH) of Xi 'an Jiaotong University (XJTU) was invited as a chief guest editor to cooperate with Professor Xu Feng from Bioinspired Engineering and Biomechanics Center (BEBC) of XJTU, Professor Silviya P. Zustiak from Saint Louis University and Professor Guy M. Genin from Washington University in Saint Louis to organize a Special Issue entitled Targeting the Physical Microenvironment of Tumors for Drug and Immunotherapy based on previous medical engineering research entitled Physical Microenvironment and Immunotherapy of Tumors for Advanced Drug Delivery Reviews, an international authoritative review journal (IF=17.873). In this Special Issue, multiple prestigious professors at home and abroad were invited to contribute high-quality reviews.
This Special Issue systematically reviews and discusses how multiple mechanical factors in tumor physical microenvironment interfere with anti-tumor immune circulation, thereby leading to immunotherapy resistance. How extracellular matrix (ECM) and vasculature, as physical barriers, impede the diffusion of drugs and inhibit the infiltration of immune cells to play a role in eliminating tumor cells. How tumor support cell populations, such as cancer-associated fibroblasts (CAFs) and tumor-associated myeloid cells (TAMCs), can exert pro-tumor growth and immunosuppressive effects. Besides highlighting the mechanism underlying the effect of physical microenvironment on immunotherapy, this Special Issue also comprehensively showcases emerging therapeutic strategies and cutting-edge research technologies targeting tumor physical microenvironment, such as tumor activated carrier-free prodrug nanoparticles (PDNPs), development and design of therapeutic drugs aimed at nuclear mechanics and mechanotransduction, recent advances in tumor organoid-on-a-chip platforms that can interact with immune system and the adoption of such models in clinical applications.
From "phenomenon" to "mechanism" and from "technology" to "clinical transformation", this Special Issue explores the relationship between TME and treatment strategies, aiming to enhance the responsiveness of drug immunotherapy by developing new strategies for breaking down physical barriers, manipulating the chemical microenvironmentof tumors and targeting force coupling signal transduction, etc. This Special Issue provides reference for therapeutic strategy of targeting physical microenvironment of the tumors.
Special Issue
Topic: Targeting the Physical Microenvironment of Tumors for Drug and Immunotherapy
Link：https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/special-issue/1067QXP5DGN
Articles：
1.Hu,HuangL.Strategiestargetingtumorimmuneandstromalmicroenvironmentandtheirclinicalrelevance.Adv Drug Deliv Rev183(2022)114137. https://doi.org/10.1016/j.addr.2022.114137
2.Shim MK, Yang S, Sun IC,Kim K.Tumor-activatedcarrier-freeprodrugnanoparticlesfortargetedcancerImmunotherapy:Preclinicalevidenceforsafeandeffectivedrugdelivery.Adv Drug Deliv Rev183(2022)114177. https://doi.org/10.1016/j.addr.2022.114177
3.NgoW,AhmedS,BlackadarC,BussinB,JiQ,MladjenovicSM,SepahiZ,ChanW.Whynanoparticlespreferlivermacrophagecelluptakeinvivo. Adv Drug Deliv Rev185(2022)114238. https://doi.org/10.1016/j.addr.2022.114238
4.LuoZ,YaoX,LiM,FangD,FeiY,ChengZ,XuY,ZhuB.ModulatingtumorphysicalmicroenvironmentforfuelingCAR-Tcelltherapy.Adv Drug Deliv Rev185(2022)114301. https://doi.org/10.1016/j.addr.2022.114301
5.ZhangT,JiaY,YuY,ZhangB,XuF,GuoH.Targetingthetumorbiophysicalmicroenvironmenttoreduceresistancetoimmunotherapy.Adv Drug Deliv Rev186(2022)114319. https://doi.org/10.1016/j.addr.2022.114319
6.ZhangJ,TavakoliH,MaL,LiX,HanL,LiX.Immunotherapydiscoveryontumororganoid-on-a-chipplatformsthatrecapitulatethetumormicroenvironment.Adv Drug Deliv Rev187(2022)114365. https://doi.org/10.1016/j.addr.2022.114365
7.HormuthDA,FarhatM,ChristensonC,CurlB,ChadQuarlesC,ChungC,YankeelovTE.Opportunitiesforimprovingbraincancertreatmentoutcomesthroughimaging-basedmathematicalmodelingofthedeliveryofradiotherapyandimmunotherapy.Adv Drug Deliv Rev187(2022)114367. https://doi.org/10.1016/j.addr.2022.114367
8.LiN,ZhangX,ZhouJ,LiW,ShuX,WuY,LongM.Multiscalebiomechanicsandmechanotransductionfromliverfibrosistocancer.Adv Drug Deliv Rev188(2022)114448. https://doi.org/10.1016/j.addr.2022.114448
9.ZhaoJ,DongY,ZhangY,WangJ,WangZ. Biophysicalheterogeneityofmyeloid-derivedmicroenvironmenttoregulateresistancetocancerimmunotherapy.Adv Drug Deliv Rev191(2022)114585. https://doi.org/10.1016/j.addr.2022.114585
10.Liu S, Li Y, Hong Y, Wang M, Zhang H, Ma J, Qu K, Huang G,Lu T.MechanotherapyinOncology:TargetingNuclearMechanicsandMechanotransduction.Adv Drug Deliv Rev194(2023)114722. https://doi.org/10.1016/j.addr.2023.114722
11.Delaram S, Guy M, Silviya P.Mechanobiologyofcancercellresponsivenesstochemotherapyandimmunotherapy:Mechanisticinsightsandbiomaterialplatforms.Adv Drug Deliv Rev196(2023)114771. https://doi.org/10.1016/j.addr.2023.114771
